The International Myeloma Working Group (IMWG) has established criteria for clinical response to treatment in PCM, which includes changes in serum/urine M-protein levels, determined by SPEP and sIFE [5,6]. The gene discussed is MYOM2; the disease is paracoccidioidomycosis.